Long-term safety and effectiveness of roflumilast cream 0.3% in adults with chronic plaque psoriasis: A 52-week, phase 2, open-label trial-Reference-Cited by-同舟云学术

Long-term safety and effectiveness of roflumilast cream 0.3% in adults with chronic plaque psoriasis: A 52-week, phase 2, open-label trial

Published:2024-08 Issue:2 Volume:91 Page:273-280
ISSN:0190-9622
Container-title:Journal of the American Academy of Dermatology
language:en
Short-container-title:Journal of the American Academy of Dermatology

Author:

Stein Gold Linda,Adam David N.,Albrecht Lorne,Alonso-Llamazares Javier,Ferris Laura K.,Gooderham Melinda J.,Hong H. Chih-ho,Kempers Steven E.,Kircik Leon H.,Lebwohl Mark,Loo Wei Jing,Nahm Walter K.,Papp Kim A.,Stewart Daniel,Toth Darryl P.,Zirwas Matthew,Krupa David,Snyder Scott,Burnett Patrick,Higham Robert,Berk David R.

Publisher

Elsevier BV

Reference15 articles.

1. The efficacy and tolerability of clobetasol propionate foam 0.05% in the treatment of mild to moderate plaque-type psoriasis of nonscalp regions;Gottlieb;J Cutan Med Surg,2003

2. A randomized, double-blind, placebo-controlled study of clobetasol propionate 0.05% foam in the treatment of nonscalp psoriasis;Lebwohl;Int J Dermatol,2002

3. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures;Elmets;J Am Acad Dermatol,2021

4. Tacrolimus ointment is effective for facial and intertriginous psoriasis;Lebwohl;J Am Acad Dermatol,2004

5. Phosphodiesterase-4 inhibitors for the treatment of inflammatory diseases;Li;Front Pharmacol,2018

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Moderne topische Arzneimittel – neue Entwicklungen in Galenik und Pharmakologie;Die Dermatologie;2024-08-27

2. Efficacy and Safety of Topical Roflumilast for the Treatment of Psoriasis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials;Clinical Drug Investigation;2024-08-22